eamdacademy.org-mMpv-1792796776-s063882182 1792796776 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2024 3 2 Daniel Fischer Laura Meier Thomas Braun Stefan Koch Felix Roth 2024 10.68159/s063882182 https://eamdacademy.org/pub/journal/3/article/s063882182 Drumond N, van Riet-Nales DA, Karapinar-Çarkit F, Stegemann S. Patients’ appropriateness, acceptability, usability and preferences for pharmaceutical preparations: Results from a literature review on clinical evidence. Int J Pharm. 2017;521(1-2):294-305. Walsh J, Ranmal SR, Ernest TB, Liu F. Patient acceptability, safety and access: A balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations. Int J Pharm. 2018;536(2):547-62. Stegemann S. Patient centric drug product design in modern drug delivery as an opportunity to increase safety and effectiveness. Expert Opin Drug Deliv. 2018;15(6):619-27. Burke MD, Keeney M, Kleinberg R, Burlage R. Challenges and opportunities for patient centric drug product design: Industry perspectives. Pharm Res. 2019;36(6):85. Janssens R, Huys I, van Overbeeke E, Whichello C, Harding S, Kübler J, et al. Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: A systematic review. BMC Med Inform Decis Mak. 2019;19(1):189. Oliveira MD, Mataloto I, Kanavos P. Multi-criteria decision analysis for health technology assessment: Addressing methodological challenges to improve the state of the art. Eur J Health Econ. 2019;20(6):891-918. Menditto E, Orlando V, De Rosa G, Minghetti P, Musazzi UM, Cahir C, et al. Patient centric pharmaceutical drug product design—The impact on medication adherence. Pharmaceutics. 2020;12(1):44. Yu LX, Kopcha M. The future of pharmaceutical quality and the path to get there. Int J Pharm. 2017;528(1-2):354-9. Homayun B, Lin X, Choi HJ. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics. 2019;11(3):129. Gonella A, Grizot S, Liu F, López Noriega A, Richard J. Long-acting injectable formulation technologies: Challenges and opportunities for the delivery of fragile molecules. Expert Opin Drug Deliv. 2022;19(8):927-44. Stegemann S, Sheehan L, Rossi A, Barrett A, Paudel A, Crean A, et al. Rational and practical considerations to guide a target product profile for patient-centric drug product development with measurable patient outcomes: A proposed roadmap. Eur J Pharm Biopharm. 2022;177:81-8. Timpe C, Stegemann S, Barrett A, Mujumdar S. Challenges and opportunities to include patient-centric product design in industrial medicines development to improve therapeutic goals. Br J Clin Pharmacol. 2020;86(10):2020-7. Algorri M, Cauchon NS, Christian T, O'Connell C, Vaidya P. Patient-centric product development: A summary of select regulatory CMC and device considerations. J Pharm Sci. 2023;112(4):922-36. Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: The case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023;22(5):387-409. Bauer A, Berben P, Chakravarthi SS, Chattorraj S, Garg A, Gourdon B, et al. Current state and opportunities with long-acting injectables: Industry perspectives from the Innovation and Quality Consortium “Long-Acting Injectables” Working Group. Pharm Res. 2023;40(7):1601-31. Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: Results of a systematic review and expert consultation across eight European countries. Eur J Health Econ. 2018;19(1):123-52. Al Fatease A, Abdelkader H. Recent advances in long-acting drug delivery and formulations. Pharmaceutics. 2023;15(11):2519. Stevenson J, Poker R, Schoss J, Campbell M, Everitt C, Holly B, et al. Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design. Adv Drug Deliv Rev. 2024;209:115322. Navas C, Minton AP, Rodriguez-Leboeuf AM. The role of patient-reported outcomes to measure treatment satisfaction in drug development. Patient. 2024;17(6):603-15. Su P, Zhi K, Xu H, Xiao J, Liu J, Wang Z, et al. The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: A literature review. Front Pharmacol. 2024;15:1245825. Tandon A, Cobb B, Centra J, Izmailova E, Manyakov NV, McClenahan S, et al. Human factors, human-centered design, and usability of sensor-based digital health technologies: Scoping review. J Med Internet Res. 2024;26:e57628. Sánchez-Martínez FI, Abellán-Perpiñán JM, Martínez-Pérez JE, Gómez-Torres JL. Design of a multiple criteria decision analysis framework for prioritizing high-impact health technologies in a regional health service. Int J Technol Assess Health Care. 2024;40(1):e21. Almeida D, Umuhire D, Gonzalez-Quevedo R, António A, Burgos JG, Verpillat P, et al. Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU. Front Med (Lausanne). 2024;11:1408636. Mire-Sluis A, Dobbins J, Moore CM, Pepper T, Rellahan B, Riker K, et al. Patient-centric quality standards. J Pharm Sci. 2024;113(4):837-55.